Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter ...

Noida (Uttar Pradesh) [India], February 25: As India advances its ambition to become a global centre for healthcare ...

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C ...

The 10 winners of the annual Undergraduate Poster Award Competition (UPAC) were recognized at the 70th Biophysical Society Annual Meeting Poster Awards Ceremony on February 23, 2026. After two rounds ...

Niagen Bioscience Inc (NASDAQ:NAGE) Q4 2025 Earnings Call Transcript March 4, 2026 Niagen Bioscience Inc beats earnings expectations. Reported EPS is $0.05, expectations were $0.02. Operator: Ladies ...

A “living drug” was developed as a cancer treatment. Now it is showing promise for conditions, such as lupus and multiple sclerosis, that have long been considered incurable.

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatap ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 9:50 AM ESTCompany ParticipantsRamy Farid - CEO, President ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

Chemistry World provides expert, independent science journalism for the global chemical science community. We are part of the ...

Q4 2025 earnings call recap: pemvidutide Phase III MASH plans, Phase II data, FDA status, cash runway to 2028—read now.

Bio-based polyhydroxyalkanoates (PHAs) are considered one of the most promising sustainable alternatives to fossil-derived plastics. Poly[(D-lactate)-co-(R)-3-hydroxybutyrate] (LAHB) is an ...